Medication leaflets

Active substance

Results for the substance bevacizumab

14 results

About this active substance

Bevacizumab is a monoclonal antibody used in the treatment of various cancers, including metastatic colorectal cancer, non-small cell lung cancer, metastatic breast cancer, ovarian cancer, and glioblastoma. It works by inhibiting vascular endothelial growth factor (VEGF), a protein that promotes the formation of new blood vessels (angiogenesis). By blocking VEGF, bevacizumab reduces the blood supply to the tumor, thereby slowing its growth and spread.

The medication is administered intravenously, usually in combination with other anticancer therapies, according to a schedule determined by the doctor. The dosage and frequency depend on the type of cancer being treated and the patient’s overall condition.

Common side effects include high blood pressure, fatigue, bleeding, abdominal pain, nausea, and diarrhea. Rare but serious complications may include gastrointestinal perforations, fistula formation, or impaired wound healing.

Bevacizumab is contraindicated in patients with hypersensitivity to the active substance or any of its excipients. Its use during pregnancy is discouraged, as it may negatively affect fetal development. Close monitoring of patients during treatment is essential to identify and manage potential adverse effects.